Phase 2 Trial of Moderately High Dose Single Agent Mitoxantrone in Platinum and Paclitaxel-Refractory Ovarian Cancer
- 31 July 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 70 (1), 123-126
- https://doi.org/10.1006/gyno.1998.5044
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.Journal of Clinical Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Phase I–II intraperitoneal mitoxantrone in advanced pretreated ovarian cancerEuropean Journal Of Cancer, 1993
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992
- Mitoxantrone: an active, new antitumor agent with an improved therapeutic indexCancer Treatment Reviews, 1987
- Phase-I Study of Intraperitoneal Mitoxantrone – Clinical and Pharmacokinetic EvaluationOncology Research and Treatment, 1987
- Mitoxantrone (NSC-3O1739) in patients with advanced ovarian carcinomaAmerican Journal of Clinical Oncology, 1984